Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | PTGIR | P43119 | 2/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211925 | 0.88 | SIGMAR1 (0.51) | SIGMAR1ABCB1PTGIRPTGDR | |
| SCHEMBL5211943 | 0.87 | SIGMAR1 (0.38) | SIGMAR1ABCB1PTGIRPTGDRPARP1 | |
| SCHEMBL5211044 | 0.80 | SIGMAR1 (0.40) | SIGMAR1ABCB1PTGIRPTGDRCNR1 | |
| SCHEMBL5210680 | 0.78 | PTGIR (0.39) | SIGMAR1ABCB1PTGIRPTGDRPARP1 | |
| SCHEMBL5212129 | 0.74 | PTGIR (0.42) | SIGMAR1ABCB1PTGIRPTGDRPARP1 | |
| SCHEMBL5422415 | 0.73 | PPARG (0.46) | — | |
| SCHEMBL5211828 | 0.72 | PTGIR (0.44) | SIGMAR1PTGIRPTGDRPARP1 | |
| SCHEMBL5110512 | 0.71 | ALDH1A1 (0.51) | PTGIRPTGDRCA12CA1CA2 | |
| SCHEMBL5211490 | 0.70 | PTGIR (0.41) | SIGMAR1ABCB1PTGIRPTGDR | |
| SCHEMBL10860909 | 0.69 | MTNR1A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1354879-B1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1354879-B1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220864-B2 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-12-21 | — | — | US | disclosed |
| EP-1726586-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1354879-A1 | DIHYDRONAPHTHALENE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287304-A1 | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | SREBF1, NR1H2, NR1H3 | SIGMAR1 1017/4885ABCB1 561/4885PTGIR 376/4885 |
| US-20040138213-A1 | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | SREBF1, NR1H2, NR1H3 | SIGMAR1 542/4885ABCB1 225/4885PTGIR 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.